The oncology testing specialist reported strong top-line growth, but also rising costs and ongoing net losses.

Adjusted earnings per share of $1.88 edged past the forecasted $1.82. Revenue in Q4 hit $1.36 billion, exceeding the $1.35 billion forecast. This marked a solid quarter, reflecting robust growth in key segments despite competitive challenges.